Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma (Q41316099)

16 January 2018

title

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma (English)

1 reference

16 January 2018

2

Bernard Escudier

1 reference

16 January 2018

Frede Donskov

14

0 references

John Wagstaff

John Wagstaff

16

0 references

Giuseppe Procopio

Giuseppe Procopio

9

0 references

Alain Ravaud

Alain Ravaud

23

0 references

Howard Gurney

Howard Gurney

13

0 references

Robert Motzer

Robert J Motzer

1

0 references

Toni K Choueiri

12

Toni K Choueiri

1 reference

16 January 2018

author name string

David F McDermott

3

1 reference

16 January 2018

Saby George

4

1 reference

16 January 2018

Hans J Hammers

5

1 reference

16 January 2018

Sandhya Srinivas

6

1 reference

16 January 2018

Scott S Tykodi

7

1 reference

16 January 2018

Jeffrey A Sosman

8

1 reference

16 January 2018

Elizabeth R Plimack

10

1 reference

16 January 2018

Daniel Castellano

11

1 reference

16 January 2018

Petri Bono

15

1 reference

16 January 2018

Thomas C Gauler

17

1 reference

16 January 2018

Takeshi Ueda

18

1 reference

16 January 2018

Yoshihiko Tomita

19

1 reference

16 January 2018

Fabio A Schutz

20

1 reference

16 January 2018

Christian Kollmannsberger

21

1 reference

16 January 2018

James Larkin

22

1 reference

16 January 2018

Jason S Simon

24

1 reference

16 January 2018

Li-An Xu

25

1 reference

16 January 2018

Ian M Waxman

26

1 reference

16 January 2018

Padmanee Sharma

27

1 reference

16 January 2018

CheckMate 025 Investigators

28

1 reference

16 January 2018

language of work or name

English

0 references

publication date

25 September 2015

1 reference

16 January 2018

The New England Journal of Medicine

published in

1 reference

16 January 2018

volume

373

1 reference

16 January 2018

page(s)

1803-1813

1 reference

16 January 2018

issue

19

1 reference

16 January 2018

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Nivolumab in previously untreated melanoma without BRAF mutation

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

New agents in renal cell carcinoma

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Cytokines in cancer immunotherapy

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Current and future systemic treatments for renal cell carcinoma

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Molecular mechanisms of T-cell tolerance.

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Development and validation of a scale to measure disease-related symptoms of kidney cancer

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

A Multiple Testing Procedure for Clinical Trials

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy

14 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5719487

Karnofsky performance status revisited: reliability, validity, and guidelines

19 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26406148

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1510665

1 reference

16 January 2018

PMCID

5719487

1 reference

16 January 2018

PubMed ID

26406148

1 reference

16 January 2018